T. Rowe Price Associates
TSHA icon

T. Rowe Price Associates’s Taysha Gene Therapies TSHA Stock Holding History

T. Rowe Price Associates’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
199,494
+40,540
+26% +$240K ﹤0.01% 2176
2026
Q1 		$711K Buy
158,954
+37,140
+30% +$173K ﹤0.01% 2300
2025
Q4 		$670K Buy
121,814
+7,979
+7% +$38.7K ﹤0.01% 2267
2025
Q3 		$373K Buy
113,835
+29,232
+35% +$82.8K ﹤0.01% 2500
2025
Q2 		$196K Buy
84,603
+10,578
+14% +$23K ﹤0.01% 2722
2025
Q1 		$103K Buy
74,025
+8,694
+13% +$14.5K ﹤0.01% 2816
2024
Q4 		$114K Buy
65,331
+5,612
+9% +$11.6K ﹤0.01% 2812
2024
Q3 		$121K Sell
59,719
-1,216,859
-95% -$2.67M ﹤0.01% 2784
2024
Q2 		$2.86M Buy
1,276,578
+177,249
+16% +$516K ﹤0.01% 1411
2024
Q1 		$3.16M Sell
1,099,329
-128,004
-10% -$267K ﹤0.01% 1367
2023
Q4 		$2.17M Sell
1,227,333
-20,138
-2% -$40.1K ﹤0.01% 1483
2023
Q3 		$3.94M Buy
+1,247,471
New +$2.33M ﹤0.01% 1231

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates's TSHA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Taysha Gene Therapies (TSHA) stake by 26% in Q2 2026, buying an estimated $240K and bringing the position to 199,494 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

T. Rowe Price Associates first reported a position in TSHA in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.94M in Q3 2023. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • T. Rowe Price Associates held 199,494 shares of Taysha Gene Therapies worth $1.36M as of Q2 2026.
  • T. Rowe Price Associates bought 40,540 Taysha Gene Therapies shares in Q2 2026, an estimated $240K.
  • Taysha Gene Therapies made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2176 holding.
  • T. Rowe Price Associates first reported a position in Taysha Gene Therapies in Q3 2023 and has held it in 12 quarters since.
  • T. Rowe Price Associates's Taysha Gene Therapies position peaked at $3.94M in Q3 2023.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.